Eternygen today announced the first closing of its Series A2 funding round led by new anchor investor Evotec SE and additional funding from venture capital firms Epidarex Capital, IBB Ventures and a number of family offices. The new investment amounting to € 5 m will be used to drive Eternygen’s development of novel treatments for non-alcoholic steatohepatitis („NASH“) to the next milestone, i.e. the selection of a preclinical development candidate, the initiation of IND enabling studies as well as growing clinical capabilities within the team. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/eternygen-announces-the-first-closing-of-its-series-a2-funding-round-5988